US FDA’s New ‘Plausible Mechanism Of Action’ Pathway Limited To Bespoke Therapies

 
• By Sue Sutter
  
Lonely pathway
The FDA's "plausible mechanism of action" pathway will be limited to individualized treatments. (Shutterstock)

More from Rare Diseases

More from Duke-Margolis Center for Health Policy